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Abstract
Thyroid nodule is a common presentation and requires a structured diagnostic approach to ascertain the risk of 
malignancy and determine appropriate management. This review article highlights the key points in the history and 
examination which can help with risk stratification. It also discussed the application of fine needle aspiration cytology 
findings and the British Thyroid Association Guidelines in clinical practice.
Introduction
Although thyroid nodule is a common presentation, thy-
roid cancer is rare. Thyroid nodules can be detected by
palpation in 10% of women and 2% of men [1]. The prev-
alence of thyroid nodules can be 50% or more if ultra-
sonography was used [1]. On the other hand, the annual
incidence of thyroid cancer in the UK was reported at 3.5
per 100,000 women and 1.3 per 100,000 men [1]. Thyroid
cancer is the most common endocrine malignancy but
only represents 1% of all malignancies [1]. It is therefore
crucial to have a clear diagnostic approach to ensure
patients presenting with thyroid nodules are managed
appropriately and are not over or under-treated. Thyroid
cancer has a favourable prognosis and accounts for less
than 0.5% of cancer deaths [2].
Clinical assessment
It is important to obtain a good history focusing on the
gender (male has a higher risk) and age at presentation
should be noted. The risk of malignancy is increased for
thyroid swelling in patients less than 16 years old and
above 45 years old. It should include the duration of the
thyroid swelling and, more importantly, the rate at which
it is growing. History of neck irradiation and family his-
tory of thyroid cancer should be noted. Other associated
s y m p t o m s  s u c h  a s  d i f f i c u l t y  s w a l l o w i n g  o r  b r e a t h i n g
would suggest compressive effect from the thyroid swell-
i ng. A hoa rse  voi c e  is  a  st r ong  indica t io n of  r ecu rr e n t
laryngeal nerve palsy and malignancy [3,4]. These are
summarized in Table 1.
Examination of the neck should include palpation of
the thyroid gland to determine the characteristics (size,
consistency, mobility, cystic, single nodule, multinodular,
or dominant nodule in multinodular goiter) and for any
palpable cervical lymphadenopathy. A note should be
made about voice quality and if in any doubt, a clinic flex-
ible laryngoscopy to directly visualise and assess the
movement of the vocal cords could be performed. These
are summarized in Table 1.
Patients with difficulty breathing (increase respiratory
rate or decrease oxygen saturation) or stridor should be
referred as an emergency and be seen on the same day.
Serological investigations
Routine Thyroid Function Test (TFT) including Thyroid
Stimulating Hormone (TSH) should be performed to
determine the patient's thyroid status. T3 and T4 levels
will be required if TSH level was abnormal. When hypo-
thyroidism is confirmed, Thyroid Peroxidase Antibodies
(TPA) should be requested to check for auto-immune
thyroid disease such as Hashimoto's thyroiditis. Thyro-
globulin level does not help in the initial management of
thyroid nodule and therefore is not recommended.
Basal plasma calcitonin levels may be useful if Medul-
lary Thyroid cancer (MTC) is suspected such as when
there is a family history of medullary thyroid cancer or
paraneoplastic syndromes. These may include Cushing's
syndrome (ACTH) or carcinoid syndrome with watery
diarrhoea and vasomotor flushing. Clinician should also
be vigilant for pheochromocytoma which is associated
with MTC in Multiple Endocrine Neoplasia (MEN) Type
II. Patients with pheochromocytoma can present with
sympathetic nervous system hyperactivity such as anxi-
ety, palpitations, tremor, hypertension and cardiac
arrhythmias.
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Biopsy and Imaging
Fine needle aspiration cytology (FNAC) is the most
important step in the management of thyroid nodules.
FNAC has a sensitivity ranging from 65% - 98% and spec-
ificity ranging from 72% - 100% [5]. The false positive rate
for cancer varies from 0 - 7% and the false negative rate
for cancer varies from 1% - 11% [5]. FNAC can be per-
formed free-hand or ultrasound-guided to increase confi-
dence if the lesion is palpable.
Ultrasound-guided FNAC is gaining popularity and has
been found to improve accuracy of FNAC. The acellular
or non-diagnostic (Thy 1) aspirate is reduced from 14% in
free-hand FNAC to 8% in ultrasound-guided FNAC [5].
The sensitivity (from 92% to 98%) and specificity (from
69% to 71%) of FNAC was also improved with ultrasound
guidance [6]. In addition, ultrasound-guided FNAC can
be used to help localise impalpable lesion, lesions less
than 1 cm, or when initial free-hand FNAC was non-diag-
nostic.
Core biopsy (with or without ultrasound guidance)
should be considered after two aspiration procedures
showing non-diagnostic specimen (Thy 1) or when a thy-
roid lymphoma was suspected. Thyroid lymphoma typi-
cally presents with a rapidly increasing neck swelling in
an elderly woman or on a background of autoimmune
thyroiditis.
Cytology results can be placed in 5 diagnostic catego-
ries (Thy 1 - Thy 5) as indicated by the British Thyroid
Association guidelines [1]. This will help with subsequent
management and is summarised in Table 2 (Figure 1 and
2) below:-
Given the above false-negative rate of FNAC results,
the probability of a benign thyroid nodule being accu-
rately diagnosed as benign from a single FNAC is 90%.
However, the accuracy of diagnosis increases significantly
to 98% if two separate aspirates were performed on sepa-
rate occasions [7]. As such, having 2 aspirates decreases
the false negative rate to 1.2% [7]. A diagnostic flowchart
is shown in Figure 3.
Ultrasound can be used to accurately document the
size of thyroid swelling and therefore serial scans allow
better assessment of growth. Certain ultrasound charac-
teristics on thyroid swelling have been shown to be asso-
ciated with higher or lower risk of malignancy. Comet tail
sign and coarse calcification suggests very low risk of
malignancy. Hypoechoicity and absent halo with indis-
tinct margin are associated with moderate risk of malig-
nancy . T he pr esence of microcalcifica tion (F igure 4) is
highly suggestive of malignancy and especially papillary
carcinoma [4,7].
Computed Tomography (CT) and Magnetic Resonance
Imaging (MRI) are necessary in some cases to determine
Table 1: Risk factors for thyroid malignancy. Baseline UK 
annual incidence for thyroid cancer: 2 - 3/100,000 
population .
Risk factors Risk of malignancy
Gender [4,9] Male: 2 - 3 times increased risk.
Age [4,8] Less than 20: Risk of malignancy 
doubled.
Above age 45: Increased risk of 
malignancy.
Above 70: Risk of malignancy 
quadrupled.
Ionising radiation [3,10] Latency period is usually 10 - 15 
years and mostly occurs 20 - 30 
years after exposure.
There is a 40% absolute risk of 
malignancy for a thyroid nodule 
in a patient with previous 
radiation exposure [9].
Low dose: 100 times increase 
risk of malignancy (lifetime risk).
High dose: 300 times increase 
risk of malignancy (lifetime risk).
Family history [3] Presence of thyroid cancer in 
family members increases risk of 
malignancy.
Tumour size [4,11] The larger the tumour size, 
especially when >4 cm, or the 
presence of obstructive 
symptoms indicates higher risk 
of malignancy.
Rate of growth [3,10,11] History of rapid growth in a few 
weeks indicates higher risk of 
malignancy.
Hoarse voice or vocal cord palsy 
with recurrent laryngeal nerve 
involvement [11]
Presence of hoarse voice or 
vocal cord palsy indicates high 
risk of malignancy.
Cervical lymphadenopathy [11] Presence of cervical 
lymphadenopathy indicates 
high risk of malignancy.
Characteristics of thyroid 
swelling [11]
Firm/hard consistency or fixed 
swelling indicates high risk of 
malignancy.
Soft, mobile or cystic swelling 
indicates low risk of malignancy.Eng et al. Head & Neck Oncology 2010, 2:11
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the staging and extent of the disease, and in planning sur-
gery. CT and/or MRI is indicated when there is presence
of a fixed thyroid mass or patients with haemoptysis indi-
cating potential involvement of surrounding structures.
Other important indications include cervical lymphade-
nopathy or when limits of the goiter cannot be deter-
mined clinically such as retrosternal goitre. CT or MRI
can demonstrate involvement of the larynx, pharynx, tra-
chea, oesophagus or major blood vessels. CT can also
help in detecting pulmonary metastasis. It is important to
avoid iodine-contrast media in CT scan to ensure subse-
quent radioiodine treatment uptake by remaining thyroid
tissue is not compromised. This difficulty may be over-
come by requesting for Gadolinium-enhanced MRI scan.
Euthyroid clinically palpable solitary nodule or nodule > 1 
cm
These patients have the highest risk of thyroid cancer for
all patients presenting with thyroid nodules (up to 20%
will be malignant) [3]. They should be carefully evaluated
and managed in accordance with the results of fine nee-
dle aspiration cytology.
In high risk clinical group (Table 1) or lesions with sus-
picious ultrasound characteristics previously described,
despite benign FNAC (Thy 2), diagnostic lobectomy may
sometimes be appropriate after MDT discussion.
Follicular and Hurthle cell lesions are commonly asso-
ciated with Thy 3 Classification. This is because these 2
lesions can only be differentiated by the presence or
Table 2: FNAC Diagnostic categories and recommended actions
Diagnostic category Description Recommended action
Thy 1 Non-diagnostic, insufficient sample.
Cyst containing colloid or histiocytes only, in the 
absence of epithelial cells.
To repeat FNAC. Ultrasound-guidance may help.
If cyst aspirated to dryness with no residual swelling, 
clinical/ultrasound follow-up alone may be 
sufficient.
Thy 2 Benign, non-neoplastic.
Cyst containing benign epithelial cells.
Repeat FNAC in 3 - 6 month. Two non-neoplastic 
results 3 - 6 months apart should exclude neoplasia.
Thy 3 Follicular or Hurthle cell lesion/suspected follicular or 
Hurthle neoplasm.
(Figure 1)
MDT discussion - diagnostic lobectomy.
Thy 4 Suspicious of malignancy.
(Figure 2)
MDT discussion - surgical intervention, e.g. Total 
thyroidectomy.
Thy 5 Diagnostic of malignancy. MDT discussion - surgical intervention, e.g. Total 
thyroidectomy.
Figure 1 Thyroid follicular cells in a microfollicular pattern (Thy 
3).
Figure 2 Cytology of a Papillary Thyroid carcinoma. Showing the 
fibrovascular core and an intranuclear inclusion (arrowed).Eng et al. Head & Neck Oncology 2010, 2:11
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absence of capsular, vascular or lymphatic invasion on
histological examination. Furthermore, these lesions have
been noted to have a malignancy rate of 10% - 30% [8].
Surgical management of these lesions is usually indicated
after MDT discussion.
Thyroid nodule associated with Hypo/Hyper-thyroidism
These nodules are very unlikely to be cancer. They are
more likely to be benign toxic nodule or Hashimoto's thy-
roiditis. The frequency of malignancy in cold nodules is
10 - 20% and only 4% in hot nodules [3,9].
These nodules should still be aspirated and if con-
firmed to be benign (Thy 2) after 2 aspirates 3 - 6 months
apart, with no other suspicious features, can be safely
managed by an endocrinologist. These patients can be
referred back for re-evaluation if there was any change in
the swelling.
Thyroid cystic swelling
Thyroid cyst should be clearly stated to help pathologist
in interpreting FNAC. Cyst should be aspirated to dry-
ness and it is important to note whether there is any
residual mass. Any residual mass should be immediately
aspirated and send as separate specimen [1].
For thyroid cyst that is shown to be benign on FNAC
and does not recur at follow-up, clinical observation
alone may be sufficient.
Recurrent thyroid cyst should be re-aspirated during
follow-up and sample sent for cytological examination.
Patients with high risk factors in history and examination
can be considered for diagnostic lobectomy. Some sur-
geons would consider diagnostic lobectomy for cyst that
has recurred for 3 times or more (anecdotal evidence).
Surgery can also be considered at patient's request.
Dominant nodule in multinodular goiter
Patients with hyper- or hypothyroidism associated with
multinodular goiter with no other suspicious features in
history and clinical examination have a low risk of thyroid
cancer1. These patients are routinely referred to an endo-
crinologist.
When a dominant nodule is noted to be growing and
become suspicious, it should be aspirated and treated
accordingly depending on cytology results.
Low-risk patients who are euthyroid with multinodular
goiter that has been present for years, and has not
changed in size, have a very low risk of thyroid cancer [1].
These patients can be observed at intermediate or long
intervals.
Figure 3 Thyroid Nodule management flow chart.
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Clinically non-palpable incidental thyroid swelling < 1 cm 
('Incidentalloma')
These are not uncommonly noted during surgery or
imaging performed for another purpose. In patients with
low risk characteristics (as per history, examination, USS
findings), these nodules have very low risk of cancer [1].
In addition, there is no evidence to show that treatment
of subcentimeter microcarcinomas improves outcome
[2,9].
The exception to the above is an 'incidentalloma' identi-
fied by FDG-PET scan. It was shown that these carry a
50% chance of malignancy and therefore should be man-
aged as per a solitary thyroid nodule [9]. Likewise, 'Inci-
dentalloma' larger than 1 cm should also be managed as
per a solitary thyroid nodule.
Conclusion
Thyroid nodule is a common clinical presentation and it
is important to have clear diagnostic framework to ensure
appropriate management of these patients. Although fine
needle aspiration cytology forms the cornerstone of diag-
nosis, good history and examination will help stratify the
risk of malignancy and ultimately the best management
option chosen.
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Figure 4 Ultrasound features: Micro-calcification - histology 
proven papillary carcinoma. Hypoechoic, ill-defined margin, internal 
microcalcifications.